公开(公告)号：EP1896619A2

公开(公告)日：2008-03-12

申请号：EP06785052.9

申请日：2006-06-16

申请人： Merck & Co., Inc. ,  ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. ,  Rosetta Inpharmatics LLC.

发明人： ESPESETH, Amy, S. ,  HAZUDA, Daria ,  GATES, Adam, T. ,  MIGLIACCIO, Giovanni ,  DE FRANCESCO, Raffaele ,  LINSLEY, Peter

IPC分类号： C12Q1/70

CPC分类号： C12N15/111 ,  C12N2310/14 ,  C12N2320/12 ,  C12N2330/31 ,  C12Q1/70 ,  C12Q1/707

摘要： Liver expressed proteins involved in HCV replication were identified using a procedure measuring the effect of inhibiting expression of host cell proteins on HCV replicon activity. The identified proteins and encoding nucleic acid provide targets for inhibiting HCV replication and for evaluating the ability of compounds to inhibit HCV replication. Compounds inhibiting HCV replication include compounds targeting identified proteins and compounds targeting nucleic acid encoding the identified protein. Several of the host genes identified as targets for inhibiting HCV replication were also found to be a target for inhibiting HIV replication. The ability to serve as a target for inhibiting both HIV and HCV replication indicates that such an identified gene and encoded protein may be a useful target for inhibiting replication of different types of viruses and not limited to inhibiting replication of a particular virus.

公开(公告)号：EP1663114A2

公开(公告)日：2006-06-07

申请号：EP04788714.6

申请日：2004-09-14

申请人： Merck & Co., Inc.

发明人： EMINI, Emilio, A. ,  SHIVER, John, W. ,  CASIMIRO, Danilo, R. ,  HAZUDA, Daria ,  SCHLEIF, William, A.

IPC分类号： A61K6/00

CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/15071 ,  C12N2740/16134 ,  C12N2740/16222

摘要： The present invention provides an improved method for eliciting a therapeutic immune response in an individual infected with human immunodeficiency virus ("HIV"). The method comprises administering an adenoviral vaccine composition expressing an HIV antigen to an individual with controlled viremia. Immunization of infected individuals in this manner elicits a cellular-mediated immune response against the virus that is significant both in the level of the response and the breadth of the response. The therapeutic immune response that ensues is capable of effectively maintaining low titers of virus and, thus, offers the prospect of reducing individual dependency on antiviral therapy.